Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SYDNEY, Australia, July 17, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) would like to update shareholders on its current financial status subsequent to the closing of the recent U.S. capital raise and yesterday’s announcement of the expected 2nd milestone payment from Novartis.
Cash balance as at 30 June 2017 was AU$12.3 million. The additional proceeds received in July from the U.S. capital raise to accredited and institutional investors of approximately US$5.0 million (equivalent to approximately AU$6.5 million) together with the expected milestone payment from Novartis of US$1.0 million (equivalent to approximately AU$1.3 million) has extended the operational cash reach well into the last quarter of calendar year 2018, based on current management forecasts.
About Prima BioMed
Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Mr Matthew Gregorowski, Citadel-MAGNUS +61 (0) 422 534 755; [email protected]
